The Technical AnalystExchange: EURONEXT Industry: Diagnostics & Research
Novacyt SA Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.41% €0.721
America/New_York / 17 mai 2024 @ 11:38
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 50.92 mill |
| EPS: | -0.420 |
| P/E: | -1.720 |
| Earnings Date: | Apr 25, 2024 |
| SharesOutstanding: | 70.63 mill |
| Avg Daily Volume: | 0.192 mill |
| RATING 2024-05-17 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 4/23 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | n/a | n/a | ||||
| Ebit | n/a | n/a | ||||
| Asset | n/a | n/a | ||||
| Debt | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.720 | sector: PE 17.68 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.21x |
| Company: PE -1.720 | industry: PE 8.23 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
€1.084 (50.36%) €0.363 |
| Date: 2024-05-19 |
| Expected Trading Range (DAY) |
|---|
|
€ 0.666 - 0.776 ( +/- 7.63%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | €0.721 (-0.41% ) |
| Volume | 0.0375 mill |
| Avg. Vol. | 0.192 mill |
| % of Avg. Vol | 19.55 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ALNOV.PA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ALNOV.PA
Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. It serves hospitals and corporates. The company was incorporated in 2006 and is based in Vélizy-Villacoublay, France.